Accelerating access to rotavirus vaccines
A lifeline for children in the world’s poorest countries
Diarrhea is a leading killer of young children worldwide, and rotavirus is the most common cause of severe diarrhea. In 2013, rotavirus killed 215,000 children younger than five years of age and hospitalized millions more. Countries that have introduced rotavirus vaccines have experienced reductions in severe and fatal diarrhea, underscoring the incredible potential for rotavirus vaccines to improve child health and save lives.
Resources on this site
- Rotavirus disease overview
- Rotavirus vaccines overview
- Key messages | Key messages on rotavirus disease and vaccines
- FAQ | Frequently asked questions on rotavirus disease and vaccines
- Country introduction maps and spreadsheet | Worldwide and Gavi-eligible rotavirus vaccine introductions
- Vaccine impact data | Data tables showing reductions in hospitalizations and deaths after rotavirus vaccine introductions
- Fact sheets | Global, regional, and country-specific
- Ressources en français | Rotavirus resources translated into French
Sign up for RotaFlash e-news alert
PATH’s RotaFlash is an e-news alert that provides breaking scientific news and updates on progress made by PATH and partners toward increasing global access to vaccines against rotavirus, the leading cause of severe diarrhea in young children worldwide.
PATH’s approach: Providing expertise, tools, and evidence to support rotavirus vaccine access and sustainability
PATH is working to accelerate access to rotavirus vaccines and sustain their implementation and use in countries where children need them most urgently by:
- Increasing awareness of the burden of rotavirus disease and demonstrating that rotavirus vaccines play an essential and lifesaving role in comprehensive diarrhea control strategies.
- Generating and disseminating information at the global and country level to help policymakers make informed, evidence-based decisions on the introduction, implementation, and sustained use of rotavirus vaccines.
- Conducting scientific studies to increase effectiveness of existing commercial rotavirus vaccines.
- Speeding the development of promising candidates into safe, effective, and affordable rotavirus vaccines.